Bendamustine hydrochloride
- Catalog NO.:A822804
- CAS No. : 3543-75-7
- Molecular Formula:C16H22Cl3N3O2
- Molecular Weight: 394.72
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 3543-75-7 | Appearance | |
Catalog Number | A822804 | MDL Number | MFCD01658758 |
Molecular Formula | C16H22Cl3N3O2 | Molecular Weight | 394.72 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | 1-methyl-5-bis(2-chloroethyl)amino-2-benzimidazolinebutryric acid hydrochloride | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H317-H319 | Class | |
Precautionary Statements | P280-P305+P351+P338 | Packing Group |
Description
Bendamustine hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown, this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. In October 2008, the FDA granted further approval to market Treanda for the treatment of indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. |